Mobile App

Google Play Apple Store
Best Practices for Achieving an HCV Cure
Certified CME/CNE Activity - Mini Modules
Chronic infection with hepatitis C virus (HCV) is a serious health issue for the nearly 200 million infected persons worldwide. Achievement of a SVR may be associated with improved long-term clinical outcomes, including increased survival. Because of the intricacies and challenges associated with monitoring disease status and HCV treatment, healthcare providers often turn to guideline recommendations and best practices when tailoring therapy to achieve the best results for the individual patient.

These Mini Modules will review the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations on the use of HCV regimens for HCV genotypes 1 through 6, including treatment eligibility and when to start therapy.
Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Ira Jacobson, MD
Ira Jacobson, MD
Director of Hepatology
NYU Langone Medical Center



 

Best Practices for Achieving an HCV Cure
Certified CME/CNE Activity - Mini Modules

Ira Jacobson, MD
Ira Jacobson, MD
Director of Hepatology
NYU Langone Medical Center
Chronic infection with hepatitis C virus (HCV) is a serious health issue for the nearly 200 million infected persons worldwide. Achievement of a SVR may be associated with improved long-term clinical outcomes, including increased survival. Because of the intricacies and challenges associated with monitoring disease status and HCV treatment, healthcare providers often turn to guideline recommendations and best practices when tailoring therapy to achieve the best results for the individual patient.

These Mini Modules will review the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations on the use of HCV regimens for HCV genotypes 1 through 6, including treatment eligibility and when to start therapy.
Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Ira Jacobson, MD
Ira Jacobson, MD
Director of Hepatology
NYU Langone Medical Center





 


 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

Chronic infection with hepatitis C virus (HCV) is a serious health issue for the nearly 200 million infected persons worldwide. Achievement of a SVR may be associated with improved long-term clinical outcomes, including increased survival. Because of the intricacies and challenges associated with monitoring disease status and HCV treatment, healthcare providers often turn to guideline recommendations and best practices when tailoring therapy to achieve the best results for the individual patient.

These Mini Modules will review the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations on the use of HCV regimens for HCV genotypes 1 through 6, including treatment eligibility and when to start therapy.

Best Practices for Achieving an HCV Cure

Certified CME/CNE Activity - Mini Modules

Ira Jacobson, MD
Ira Jacobson, MD
Director of Hepatology
NYU Langone Medical Center



 


20
Supported by an independent educational grant from
Gilead Sciences Medical Affairs
Expired Activity
Mini Module
6165
  • Liver Disease
  • Archives
Liver Disease
Change Settings